Laboratorios Farmaceuticos Rovi, S.A. Stock

Equities

ROVI

ES0157261019

Pharmaceuticals

Market Closed - BME 11:35:26 2024-04-26 EDT 5-day change 1st Jan Change
85 EUR +0.35% Intraday chart for Laboratorios Farmaceuticos Rovi, S.A. +7.05% +41.20%

Financials

Sales 2024 * 824M 881M 1.2B Sales 2025 * 906M 969M 1.32B Capitalization 4.4B 4.71B 6.44B
Net income 2024 * 171M 183M 250M Net income 2025 * 206M 220M 301M EV / Sales 2024 * 5.3 x
Net cash position 2024 * 38.22M 40.87M 55.87M Net cash position 2025 * 147M 157M 215M EV / Sales 2025 * 4.7 x
P/E ratio 2024 *
25.7 x
P/E ratio 2025 *
21.8 x
Employees 1,925
Yield 2024 *
1.32%
Yield 2025 *
1.52%
Free-Float 35.68%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Laboratorios Farmaceuticos Rovi, S.A.

1 day+0.35%
1 week+7.05%
Current month+5.07%
1 month+5.39%
3 months+31.27%
6 months+72.41%
Current year+41.20%
More quotes
1 week
78.60
Extreme 78.6
86.90
1 month
77.75
Extreme 77.75
86.90
Current year
60.35
Extreme 60.35
86.90
1 year
37.96
Extreme 37.96
86.90
3 years
35.20
Extreme 35.2
86.90
5 years
17.30
Extreme 17.3
86.90
10 years
7.90
Extreme 7.9
86.90
More quotes
Managers TitleAgeSince
Chief Executive Officer - 93-12-31
Director of Finance/CFO - 99-12-31
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Director/Board Member - 94-12-31
Director of Finance/CFO - 99-12-31
Chief Executive Officer - 93-12-31
More insiders
Date Price Change Volume
24-04-26 85 +0.35% 79,264
24-04-25 84.7 +6.41% 159,176
24-04-24 79.6 -1.06% 113,717
24-04-23 80.45 +1.26% 36,685
24-04-22 79.45 +0.06% 37,668

Delayed Quote BME, April 26, 2024 at 11:35 am

More quotes
Laboratorios Farmaceuticos Rovi, S.A. specializes in the research, development, manufacturing and marketing of biological medications and specialty drugs. Net sales break down by family of products as follows: - pharmaceutical products manufactured under contract (49%); - prescription pharmaceuticals (45%): intended for preventing and treating venous thrombo-embolic disease, post-menopausal osteoporosis, muscle pain, tooth and mouth infections, angina, osteoarthritis, etc.; - diagnostic products (6%): contrast products used in medical imaging with magnetic resonance, ultrasound, or X-rays. The group also offers hospital products and non-prescription pharmaceuticals. Net sales break down by source of revenue between sales of products (50.6%), sales of services (49.3%) and sales of licenses (0.1%). Net sales are distributed geographically as follows: Spain (33%), European Union (17.3%), OECD countries (45.9%) and other (3.8%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
85 EUR
Average target price
84.1 EUR
Spread / Average Target
-1.06%
Consensus

Quarterly revenue - Rate of surprise